外科領域におけるCefroxadine (CGP-9000) の臨床使用成績 A CLINICAL STUDY ON CEFROXADINE (CGP-9000) IN SURGICAL FIELD

Access this Article

Search this Article

Author(s)

Abstract

Cefroxadine (CGP-9000, CXD) 250mgを健康成人4人に早朝空腹時経口投与させたのちの血清中濃度および尿中排泄量を測定したところ, CXDは, 2時間後平均10.7μg/mlのピーク値を示し, 比較的長く血清中濃度が維持されるようである。一方, 4時間目までの尿中排泄量は, 171.0mg (68.5%) であり, 4時間以内には, 投与量のほぼ3分の2が排泄されるようである。<BR>外科領域51例に対するCXDの臨床効果は, 著効28例, 有効19例, 無効4例となり, 有効率は92.2%であった。<BR>なお本剤と関係すると思われる副作用は1例も認められなかった。

Cefroxadine (CGP-9000, CXD), a new orally antibiotic derived from cephalosporin, has a broad spectrum and a bacteriocidal action. The authors investigated serum levels, urinary excretion, clinically effectiveness and untoward side effects of the agent. The result obtained are summarized as follows:<BR>1. Following an oral administration of 250mg CXD in 4 healthy adult volunteers, the mean serum levels showed a peak of 10.7μg/ml 2 hours after administration, with 195.2mg (78.1%) urinary excretion within 6 hours.<BR>2. CXD was given on 51 patients with infections in the field of surgery, and the result was excellent in 28 cases, good 19, poor 4, the effectiveness rate accounting for 92.2%.<BR>3. Side effects were not observed in all cases among 51 patients in CXD trial.

Journal

  • CHEMOTHERAPY

    CHEMOTHERAPY 28(Supplement3), 343-350, 1980

    Japanese Society of Chemotherapy

Codes

  • NII Article ID (NAID)
    130004193082
  • NII NACSIS-CAT ID (NCID)
    AN00186653
  • Text Lang
    UNK
  • ISSN
    0009-3165
  • NDL Article ID
    2221268
  • NDL Source Classification
    SC511(外科学)
  • NDL Source Classification
    ZS47(科学技術--医学--治療医学・看護学・漢方医学)
  • NDL Call No.
    Z19-42
  • Data Source
    NDL  J-STAGE 
Page Top